Description
Intended use:
• Sclerosteosis
• Van Buchem disease
• Osteoporosis
• Chronic Kidney Disease
• Cardiac Research
• Others
$120.00
Regulation of Bone Turnover.
Brand |
---|
Intended use:
• Sclerosteosis
• Van Buchem disease
• Osteoporosis
• Chronic Kidney Disease
• Cardiac Research
• Others
Range: | 0.05 – 3 ng/ml | ||||||||||||||||||||||||||||||
Sensitivity: | LOD: 0.009 ng/ml LLOQ: 0.058 ng/ml LOQ: 3.5 ng/ml |
||||||||||||||||||||||||||||||
Incubation time: | 4.5 hours | ||||||||||||||||||||||||||||||
Sample volume: | 25 µl | ||||||||||||||||||||||||||||||
Sample type: |
Plasma, Serum, Cell culture |
||||||||||||||||||||||||||||||
Sample preparation: |
Samples should be collected without hemolysis. Allow the blood to clot, separate serum by centrifugation and test samples within 2 hours. |
||||||||||||||||||||||||||||||
Reference values: |
Sclerostin Values are dependent on age and gender.
Clinically Healthy Subjects |
||||||||||||||||||||||||||||||
Species: |
Human |
||||||||||||||||||||||||||||||
Tests: | 96 | ||||||||||||||||||||||||||||||
Method: | ELISA |
GSA MEDICAL portfolio offers a comprehensive workflow for your lab needs with wide range of tools.
As of 2020, GSA MEDICAL INC. started providing premier Manufacturing services to the diagnostic industry. GSA MEDICAL can effectively analyze the feasibility of reagents for use in rapid immunoassays. This process offers a quick glance as to the potential a reagent or concept may have and can result in saving considerable time and money for GSAMEDICAL’s clients.
We provide strong personal support, technical competence, and experience to ensure customer expectations will be met or exceeded.
Copyright GSA Medical. All rights reserved.